CY2404B1 - Use of rapamycin derivatives in vasculopathies andxenotransplantation. - Google Patents

Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Info

Publication number
CY2404B1
CY2404B1 CY0400004A CY0400004A CY2404B1 CY 2404 B1 CY2404 B1 CY 2404B1 CY 0400004 A CY0400004 A CY 0400004A CY 0400004 A CY0400004 A CY 0400004A CY 2404 B1 CY2404 B1 CY 2404B1
Authority
CY
Cyprus
Prior art keywords
andxenotransplantation
vasculopathies
rapamycin derivatives
rapamycin
deoxyspergualine
Prior art date
Application number
CY0400004A
Other languages
English (en)
Inventor
Walter Schuler
Hendrik Schuurman
Gisbert Weckbecker
Hans-Guenter Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2404B1 publication Critical patent/CY2404B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY0400004A 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation. CY2404B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
CY2404B1 true CY2404B1 (en) 2004-09-10

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400004A CY2404B1 (en) 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation.

Country Status (30)

Country Link
US (5) US6384046B1 (de)
EP (3) EP2008657B1 (de)
JP (2) JP2000507226A (de)
KR (2) KR20070083654A (de)
CN (1) CN1124135C (de)
AT (1) ATE224194T1 (de)
AU (1) AU716514B2 (de)
BR (1) BR9708358A (de)
CA (1) CA2247275C (de)
CY (1) CY2404B1 (de)
CZ (1) CZ292483B6 (de)
DE (1) DE69715611T2 (de)
DK (2) DK0893996T3 (de)
ES (2) ES2184078T3 (de)
GB (1) GB9606452D0 (de)
HK (1) HK1018688A1 (de)
HU (1) HU226422B1 (de)
ID (1) ID17195A (de)
IL (1) IL125812A (de)
MY (1) MY117798A (de)
NO (1) NO316667B1 (de)
NZ (1) NZ331463A (de)
PL (1) PL187732B1 (de)
PT (2) PT2008657E (de)
RU (1) RU2214247C2 (de)
SI (1) SI2008657T1 (de)
SK (1) SK284343B6 (de)
TR (1) TR199801919T2 (de)
WO (1) WO1997035575A1 (de)
ZA (1) ZA972719B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6239124B1 (en) 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
DE60044717D1 (de) 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
CN100506293C (zh) 2000-03-15 2009-07-01 祥丰医疗有限公司 促进内皮细胞粘附的涂层
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
EP1709974A3 (de) * 2000-06-16 2006-12-06 Wyeth Verfahren zur behandlung von kardiovaskulären erkrankungen mit rapamycin
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
EP3406249A1 (de) * 2001-02-19 2018-11-28 Novartis AG Behandlung von brusttumoren mit einem rapamycinderivat in kombination mit einem aromatasehemmer
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
KR20050010827A (ko) * 2002-05-20 2005-01-28 오르버스 메디칼 테크놀로지즈 인코포레이티드 약물 용리 이식성 의료 장치
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2563329C (en) * 2004-04-30 2016-01-26 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (de) * 2004-12-20 2010-08-04 Ariad Pharma Inc Therapeutische stoffe und verfahren
CN102579467A (zh) 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
EP1948079A1 (de) * 2005-11-17 2008-07-30 Access Plus Co., Ltd. Röhre für die arteriovenöse verbindung und interposition für einen medizinischen eingriff
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CN101918051B (zh) 2007-11-14 2013-08-21 生物传感器国际集团有限公司 自动化涂覆设备和方法
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2352459A4 (de) * 2008-10-03 2013-09-25 Elixir Medical Corp Makrocyclische lactonverbindungen und verfahren zu ihrer verwendung
US8382818B2 (en) 2009-07-02 2013-02-26 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CA2924681C (en) 2013-09-24 2019-12-31 Giner, Inc. System for gas treatment of a cell implant
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
AU2015217349A1 (en) 2014-02-11 2016-09-08 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20170014341A1 (en) 2014-04-04 2017-01-19 Lam Therapeutics, Inc. An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
CN107249576A (zh) 2014-10-07 2017-10-13 拉姆医疗公司 用于治疗肺高压的可吸入雷帕霉素制剂
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP2019527711A (ja) 2016-08-10 2019-10-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 局所ラパマイシン療法
KR102459201B1 (ko) 2016-09-19 2022-10-27 바이오트로닉 아게 고분자-없는 약물 용출 혈관 스텐트
KR20190086489A (ko) 2016-11-15 2019-07-22 기너 라이프 사이언시즈, 인크. 피하 임플란트와 함께 이용하기에 적합한 경피 가스 확산 장치
CN109996569B (zh) 2016-12-22 2022-05-03 百多力股份公司 用于医疗装置的药物释放涂层及其制备方法
CN110831656A (zh) 2017-05-04 2020-02-21 吉纳生命科学公司 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
CN113710232A (zh) 2019-02-20 2021-11-26 人工智能治疗公司 局部雷帕霉素制剂及其在治疗面部血管纤维瘤和其他皮肤病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
KR100284210B1 (ko) * 1992-04-28 2001-03-02 이건 이. 버그 과증식성 혈관 질환 치료용 배합 제제
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2146741T3 (es) * 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
PT833828E (pt) * 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
IL125812A0 (en) 1999-04-11
HUP0001267A3 (en) 2002-01-28
ES2421455T3 (es) 2013-09-02
BR9708358A (pt) 1999-08-03
EP1149581A2 (de) 2001-10-31
PL187732B1 (pl) 2004-09-30
EP0893996A1 (de) 1999-02-03
US6384046B1 (en) 2002-05-07
CZ292483B6 (cs) 2003-09-17
US20140187574A1 (en) 2014-07-03
MY117798A (en) 2004-08-30
HK1018688A1 (en) 1999-12-30
ID17195A (id) 1997-12-11
EP2008657A3 (de) 2009-02-04
JP5124431B2 (ja) 2013-01-23
DE69715611T2 (de) 2003-05-22
SI2008657T1 (sl) 2013-07-31
CN1124135C (zh) 2003-10-15
CA2247275A1 (en) 1997-10-02
CZ307098A3 (cs) 1999-01-13
KR20070083654A (ko) 2007-08-24
NZ331463A (en) 2001-10-26
WO1997035575A1 (en) 1997-10-02
GB9606452D0 (en) 1996-06-05
NO984340D0 (no) 1998-09-18
KR20050038656A (ko) 2005-04-27
DE69715611D1 (de) 2002-10-24
PT893996E (pt) 2002-12-31
EP1149581A3 (de) 2003-12-03
AU716514B2 (en) 2000-02-24
CN1214631A (zh) 1999-04-21
RU2214247C2 (ru) 2003-10-20
HUP0001267A2 (hu) 2000-11-28
SK284343B6 (sk) 2005-02-04
EP2008657B1 (de) 2013-04-24
US20100152105A1 (en) 2010-06-17
AU2291897A (en) 1997-10-17
IL125812A (en) 2001-12-23
SK132798A3 (en) 1999-03-12
JP2000507226A (ja) 2000-06-13
PL328659A1 (en) 1999-02-15
PT2008657E (pt) 2013-07-12
DK2008657T3 (da) 2013-07-22
JP2009102349A (ja) 2009-05-14
CA2247275C (en) 2011-10-11
TR199801919T2 (xx) 1999-02-22
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
ES2184078T3 (es) 2003-04-01
US20020127248A1 (en) 2002-09-12
EP2008657A2 (de) 2008-12-31
ATE224194T1 (de) 2002-10-15
EP0893996B1 (de) 2002-09-18
US20120177690A1 (en) 2012-07-12
ZA972719B (en) 1998-09-28
HU226422B1 (en) 2008-12-29
DK0893996T3 (da) 2002-12-09
KR100836971B1 (ko) 2008-06-10

Similar Documents

Publication Publication Date Title
CY2404B1 (en) Use of rapamycin derivatives in vasculopathies andxenotransplantation.
DE68909898D1 (de) Hochfester, Stickstoff enthaltender Cermet und Verfahren zu seiner Herstellung.
IL140137A (en) Receptor bodies specifically binding tie-2 ligands
DE69205845D1 (de) Katalysatorträger, zusammensetzung und Verfahren zu seiner Herstellung.
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
PT922071E (pt) Copolimeros reticulados a base de polimeros policarboxilicos
WO2003101919A3 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
DE69112007D1 (de) Ferritischer, hitzebeständiger Gussstahl und Verfahren zu seiner Herstellung.
Giakas Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
DE602004017838D1 (de) Verfahren zur herstellung von 6-ä(4,5-dihydro-1h-imidazol-2-yl)amino-ü-7-methyl-1h-benzimidazol-4-carbonitrile und dessen bevorzugte salzform
DK0745071T3 (da) 4-Amino-6-substitueret mycophenolsyre og derivater med immunsuppressiv virkning
IL112666A0 (en) 4-amino derivatives of 5-substituted mycophenolic acid, their preparation and pharmaceutical compositions containing them
Pioli Reactivation failure in infants: A processing analysis.
RU2000124058A (ru) Способ лечения миопии
IT1241270B (it) Procedimento per realizzare vaschette di contenimento per cuscini, particolarmente cuscini di sedili per autoveicoli.
RU96119633A (ru) Способ лечения аметропий и разницы в функциональных показателях правого и левого глаза по святковской т.я.
UA36539A (uk) Спосіб проведення тренувань, що засновані на переміщеннях пацієнта, та комплекс засобів для його здійснення
ES1022409U (es) Soporte para ceniceros, posavasos y similares desechables o no desechables.
IT9053024U1 (it) Sedile per tazza di w. c. dotato di dispositivo di riscaldamento, di as pirazione e filtrazione